Minimal residual disease testing shows promising results
Research indicates strong rationale for expanding trial eligibility criteria
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Treatment may be a lifesaving option for patients with relapsed or refractory disease
A brief look at our programs
Preliminary trial reports positive patient response
Researching and operationalizing a new therapy
Molecular markers could potentially predict major adverse side effects
Advertisement
Advertisement